the drug product under normal storage conditions, potentially compromising product integrity and patient safety.

There are numerous factors influencing extractables and leachables in biologics, including:

• Container Closure System: The type of material used in the packaging (e.g., glass, plastic, elastomers) can significantly impact the release of potentially harmful substances.
• Drug Formulation: The composition of the drug product, particularly pH, buffer capacity, and other formulation components, plays a vital role in determining leachables risk.
• Storage Conditions: Temperature, humidity, and duration of storage can enhance or inhibit the extraction rate of certain compounds.

The identification of extractables and leachables is critical for performing a thorough toxicological assessment required by regulatory authorities such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and MHRA (Medicines and Healthcare products Regulatory Agency). Developing a robust E&L program will encompass a multi-step process wherein each component must be meticulously planned and executed.

Step 1: Risk Assessment of Packaging Materials

Conducting a risk assessment is the foundational step for creating an effective E&L program. This assessment should focus on identifying materials used in the container closure system that may yield extractables or leachables. The following components should be considered:

• Material Composition: Review each component’s material safety data sheets (MSDS) to understand potential leachable substances.
• Previous E&L Studies: Evaluate any historical data from prior studies or similar biologics to inform risk levels of identified extractables.
• Regulatory Guidance: Consult applicable regulatory guidelines, such as the ICH Q3C (impurities), for guidance on acceptable levels of leachables.

The output of this risk assessment will guide subsequent testing strategies and provide a baseline understanding of potential contaminants that may arise from packaging materials.

Step 2: Select Analytical Methods for E&L Testing

Choosing the appropriate analytical methods is crucial for the successful execution of E&L studies. The most commonly employed techniques include:

• GC-MS (Gas Chromatography-Mass Spectrometry): Suitable for volatile and semi-volatile extractables.
• LC-MS (Liquid Chromatography-Mass Spectrometry): Used for non-volatile and polar compounds that may leach into the biologic.
• UV-Vis Spectroscopy: For quantifying specific known leachables that absorb UV light.

When selecting analytical methods, ensure they meet the following criteria:

• Sensitivity to detect low levels of leachables.
• The ability to separate and identify complex mixtures.
• Capability for quantitative analysis, providing data for toxicological assessment.

Step 3: Conducting Extractables Studies

Extractables studies are typically performed under exaggerated conditions, utilizing different solvents, temperatures, and timeframes. This step aims to provide a conservative estimate of potential contaminants:

Designing Extractables Studies

To design effective extractables studies:

• Identify Simulants: Choose suitable solvents based on the formulation properties (e.g., water, ethanol, or oils) that may mimic expected leachables.
• Define Conditions: Establish temperature and time conditions that are realistic yet conservative to facilitate a robust evaluation (often completed over 24–30 hours).
• Sample Preparation: Execute proper leaching studies according to ISO 10993-18 methodologies to prepare samples for analysis.

Once extractables are identified, they require detailed characterization to facilitate a comprehensive toxicological assessment.

Step 4: Conducting Leachables Studies

Leachables studies aim to simulate real-world storage conditions to assess which compounds migrate into the drug product over time. The design of leachables testing should involve:

Leachables Study Design

Key considerations for leachables study design include:

• Storage Conditions: Test samples should reflect typical storage parameters to gather relevant leachables data.
• Time Points: Analyze samples at multiple time points (e.g., 0, 1, 3, 6, and 12 months) to observe how leachables may increase over time.
• Sample Size and Replicates: Ensure sufficient sample size for statistical validity and repeat testing if necessary.

Perform the analytical evaluations on leachables samples using the techniques outlined in the preceding section, ensuring that any detected compounds are recorded for further analysis.

Step 5: Toxicological Assessment of Identified Leachables

The toxicological assessment is a crucial component of the E&L program, providing vital insights into the safety of leachables detected in studies. The assessment should encompass:

Risk Characterization

To perform a toxicological risk characterization:

• Data Collection: Gather toxicological data from literature, safety databases, and existing safety assessments for detected leachables.
• California Proposition 65 and REACH Compliance: Evaluate potential regulatory compliance issues based on the leachables’ presence in propulsion and determine if they are subject to any regulatory scrutiny.
• Toxicity Evaluation: Assess the toxicity potential using established guidance from the International Council for Harmonisation (ICH) and the
  EMA.

This assessment will help to classify identified leachables according to their safety and regulatory implications.

Step 6: Documentation and Regulatory Submission

The final phase involves compiling all data from your extractables and leachables program into a comprehensive report for regulatory submission. This report should include:

Required Documentation Elements

• Summary of E&L Studies: A comprehensive overview of study design, methodologies, results, and analyses.
• Toxicological Assessment Findings: Detailed accounts of identified leachables, their potential risk, and justification for their acceptability.
• Conclusions and Recommendations: Outline any required further studies or considerations for future development stages.

Adherence to regulatory guidelines such as the FDA and EMA’s expectations for E&L documentation will be imperative for successful submission and approval of biologic products.

Conclusion

Designing a robust extractables and leachables program for biologic drug products requires diligent planning and execution across key stages. Through comprehensive risk assessments, careful selection of analytical methods, and thorough toxicological evaluations, CMC leads, packaging development teams, and toxicology professionals can ensure the safety and efficacy of biologic products. By championing a meticulous E&L program, biologic developers not only comply with regulatory mandates but also bolster the integrity of their drug products, ultimately benefitting patient health and safety.